Interleukin-17 can promote OSCC tumorigenesis by several pathways, such as provisioning the microenvironment that promotes cell transformation and tumor formation and inducing production of molecules (VEGF, MMP-9, MMP-13, CCR6, and PGE2) that promote invasiveness and angiogenesis; enhancement of immunosuppressive effects of MDSCs that promote tumor cell proliferation, survival, invasiveness and metastasis; direct proliferative effects on tumor cells; activation and transformation of stem cells. This evidence concerns the gene MMP13 and neoplasm.